Document Detail


Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions.
MedLine Citation:
PMID:  18477469     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the present study, we have investigated the effects of glycogen synthase kinase-3 (GSK-3) inhibition on infarct volume and neurobehavioral functions in a focal cerebral ischemia model. To achieve our goals, GSK-3 inhibitor II or VIII was injected at several time points and in varing dosages. GSK-3 inhibitor VIII was more effective than inhibitor II, and infarct volume and water content in the VIII group were significantly decreased 24h after the onset of ischemic stroke, as compared with the control group. These protective effects were associated with reductions of TUNEL-positive cells, neutrophil infiltration, glucose levels after ischemia, and GSK-3 enzyme activity. In addition, expressions of death and inflammation-related signals decreased and those of survival-related signals increased. Lastly, neurobehavioral functions were restored to a greater extent in the VIII group than in the control group. Together, these results suggest that GSK-3 inhibition reduces infarct volume and restores neurobehavioral functions.
Authors:
Seong-Ho Koh; A Rum Yoo; Dae-Il Chang; Se J Hwang; Seung H Kim
Related Documents :
8419009 - Ischemic preconditioning increases adenosine release and 5'-nucleotidase activity durin...
17999029 - Redox signaling at reperfusion is required for protection from ischemic preconditioning...
9815059 - Renal ischemia preconditions myocardium: role of adenosine receptors and atp-sensitive ...
6200229 - Early and late administration of a pgi2-analogue, zk 36 374 (iloprost): effects on myoc...
17825079 - Preconditioning and postconditioning: new strategies for cardioprotection.
15210139 - Brief apnea induces myocardial ischemic tolerance by an opioid-insensitive mechanism.
21463149 - Randomized trial of stents versus bypass surgery for left main coronary artery disease.
24602189 - Wearable cardioverter-defibrillator in a patient with left ventricular noncompaction/hy...
7356039 - Analysis of cardiac kinetics: use of a new photo-optic technique.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-05-12
Journal Detail:
Title:  Biochemical and biophysical research communications     Volume:  371     ISSN:  1090-2104     ISO Abbreviation:  Biochem. Biophys. Res. Commun.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-06-02     Completed Date:  2008-06-18     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0372516     Medline TA:  Biochem Biophys Res Commun     Country:  United States    
Other Details:
Languages:  eng     Pagination:  894-9     Citation Subset:  IM    
Affiliation:
Department of Neurology, College of Medicine, Hanyang University, #17 Haengdang-dong, Seongdong-gu, Seoul 133-791, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Behavior, Animal / drug effects
Blood Glucose / analysis
Brain Edema / enzymology,  etiology,  pathology*
Calcium-Binding Proteins / analysis
Caspase 3 / analysis
Cerebral Infarction / complications,  enzymology,  pathology*
Cyclooxygenase 2 / analysis
Disease Models, Animal
Glial Fibrillary Acidic Protein / analysis
Glycogen Synthase Kinase 3 / analysis,  antagonists & inhibitors*
Oxadiazoles / administration & dosage
Poly(ADP-ribose) Polymerases / analysis
Protein Kinase Inhibitors / administration & dosage*
Pyridines / administration & dosage
Rats
Rats, Sprague-Dawley
Thiazoles / administration & dosage
Urea / administration & dosage,  analogs & derivatives
Chemical
Reg. No./Substance:
0/2-thio(3-iodobenzyl)-5-(1-pyridyl)-(1,3,4)oxadiazole; 0/Aif1 protein, rat; 0/Blood Glucose; 0/Calcium-Binding Proteins; 0/Glial Fibrillary Acidic Protein; 0/N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea; 0/Oxadiazoles; 0/Protein Kinase Inhibitors; 0/Pyridines; 0/Thiazoles; 57-13-6/Urea; EC 1.14.99.1/Cyclooxygenase 2; EC 1.14.99.1/Ptgs2 protein, rat; EC 2.4.2.30/Poly(ADP-ribose) Polymerases; EC 2.7.11.26/Glycogen Synthase Kinase 3; EC 3.4.22.-/Caspase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thr308 determines Akt1 nuclear localization in insulin-stimulated keratinocytes.
Next Document:  Activated p53 induces NF-kappaB DNA binding but suppresses its transcriptional activation.